About Andreas
Andreas Katopodis is CEO of Anaveon. In 2018, he founded Anaveon together with Onur Boyman, Professor and Chair of the Department of Immunology at the University of Zurich. At Novartis, Andreas worked in the Autoimmunity, Transplantation and Inflammatory group from 1996 to 2018. He was involved in many aspects of early to late drug development for immune mediated diseases, such as solid organ transplantation and autoimmunity. Prior to this, he worked at the Zentrale Forschungslaboratorien at Ciba Geigy in Basel, doing research on immune cell trafficking. Before 1991, Andreas was an assistant professor at the Georgia Institute of Technology in Atlanta. He studied molecular biology.